CEPTOR EXECUTES LOI WITH FERRING FOR LATE-STAGE PRODUCT

CepTor Corporation, a biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced that it has signed a Letter of Intent (LOI) with Ferring International Center, S.A. in which Ferring plans to divest and CepTor plans to purchase recombinant human copper zinc superoxide dismutase (r-h CuZnSOD or SOD) for prevention of chronic respiratory morbidity in premature newborns.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=5896414)